Vote Scores

Home / Companies / Aurobindo Pharma Limited / 10 Sep 2025

Meeting · year to 30 June 202657 filers reporting

Aurobindo Pharma Limited: meeting of 10 Sep 2025

Votes reported on Form N-PX, item by item

57 Form N-PX filers reported votes at the Aurobindo Pharma Limited meeting of 10 Sep 2025. Their records fall into 4 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

2 nominees; 56.6% of reported votes for; 49 filers withheld from or voted against at least one nominee.

198 vote records from 57 filers. 2 of the 57 filers that marked the item either way voted against management.

15.8% for3.5% against80.7% other3.5% against management57 filers
2

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

99 vote records from 57 filers. 1 of the 57 filers that marked the item either way voted against management.

98.2% for0.0% against1.8% other1.8% against management57 filers100.0% for0.0% against0.0% other0.0% against management25,044,410 reported shares
3

CORPORATE GOVERNANCEIssuer

CORPORATE GOVERNANCE: management items

Management items in this category are shown together; filers word and number them differently.

184 vote records from 50 filers. 0 of the 50 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management50 filers100.0% for0.0% against0.0% against management49,829,350 reported shares, counted once per item in this group
4

OTHERIssuer

OTHER: management items

Management items in this category are shown together; filers word and number them differently.

14 vote records from 7 filers. 0 of the 7 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management7 filers100.0% for0.0% against0.0% against management259,470 reported shares, counted once per item in this group

How the largest families voted

Family1. Directors2. Auditor
VanguardSplit or no voteFor
BlackRock and iSharesSplit or no voteFor
FidelitySplit or no voteFor
DimensionalSplit or no voteFor
State Street and SPDRForFor
American CenturySplit or no voteFor
Franklin TempletonSplit or no voteFor
InvescoSplit or no voteFor
EquitableForAbstain or withhold *
Charles SchwabSplit or no voteFor
Nuveen and TIAASplit or no voteFor
John Hancock and ManulifeForFor
Morgan Stanley, Eaton Vance and CalvertAgainst *For
J.P. MorganSplit or no voteFor
Goldman SachsForFor
WisdomTreeSplit or no voteFor
Jackson National fundsSplit or no voteFor
Northern Trust and FlexSharesSplit or no voteFor
Lincoln FinancialForFor
VoyaSplit or no voteFor
Russell InvestmentsSplit or no voteFor
Brighthouse FundsForFor
Columbia ThreadneedleForFor
BNY MellonSplit or no voteFor
Pacific Life fundsSplit or no voteFor
Macquarie and Delaware FundsSplit or no voteFor

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Aurobindo Pharma Limited meeting?

57 Form N-PX filers reported votes at the meeting of 10 Sep 2025. The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Aurobindo Pharma Limited on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Aurobindo Pharma Limited

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Aurobindo Pharma Limited with a meeting date within three days of 10 Sep 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.